Portola Anticipates "Best In Class" Status For Oral Anticoagulant Betrixaban
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Portola Pharmaceuticals is launching a 500-patient Phase II safety and efficacy trial for its novel oral Factor Xa inhibitor anticoagulant betrixaban, touting the compound's potential for three significant areas of differentiation from other late-stage candidates in the crowded anti-thrombotic class
You may also be interested in...
Last Of The Primary Care Blockbusters? New Antithrombotics Line Up To Unseat Warfarin, Heparins, Plavix
Although the mainstays of antithrombotic therapy have remained the same for decades, a lengthy R&D assault by pharma – including some of the largest clinical trials ever conducted – has produced potential game-changers that have made it to FDA review for both major blood clot approaches: anticoagulation and platelet inhibition.
Safety Results Prompt Bristol To Refine Apixaban Dosing In Acute Coronary Syndrome Trials
Firm is discussing Phase III design with regulators.
With European Approval Imminent, J&J/Bayer File Rivaroxaban In The U.S.
Novel anticoagulant for orthopedic surgery poised to reach market before Pfizer, Bristol, Astellas and Daiichi Sankyo compounds.